Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Genitourinary (GU) malignancies have limited treatment options despite advances in immunotherapy.
• Immunotherapy, particularly immune checkpoint inhibitors, shows efficacy in urothelial and renal cell carcinomas but not prostate cancer.
• High morbidity and mortality persist in GU neoplasms, highlighting the need for novel therapeutic strategies like cancer vaccines.

Purpose of the Study:

• To review recent advances in cancer vaccine therapy for genitourinary malignancies.
• To summarize the current landscape of vaccine development for prostate, urothelial, and renal cancers.

Main Methods:

• A systematic literature search was conducted using PubMed, Embase, and Cochrane Database.
• The search focused on clinical trials published within the last ten years.
• Studies specifically investigating cancer vaccines in prostate, urothelial, and renal cancers were included.

Main Results:

• Various therapeutic vaccine platforms (DNA, RNA, peptide, dendritic cell, viral vector, modified tumor cells) have been developed.
• These vaccines can induce specific immune responses in a subset of patients.
• Observed immune responses infrequently translated into significant improvements in patient survival.

Conclusions:

• Further preclinical and clinical research is essential to enhance cancer vaccine efficacy in GU malignancies.
• Optimizing dosage, identifying driver targets, and overcoming resistance mechanisms are key areas for future studies.
• Combination strategies involving cancer vaccines may offer more effective and durable treatment outcomes.